Literature DB >> 17353161

An association study of inflammatory cytokine gene polymorphisms in Fabry disease.

Rachael Safyan1, Catharina Whybra, Michael Beck, Deborah Elstein, Gheona Altarescu.   

Abstract

BACKGROUND: Fabry disease is an X-linked disorder associated with early-onset stroke, cardiomyopathy, and progression to end-stage renal failure. Correlations between inflammatory cytokines have been shown in other lysosomal storage diseases. The aim of the study was to evaluate functional gene polymorphisms of key pro- and anti-inflammatory cytokines and to correlate them to a clinical score to assess the potential role of inflammation in Fabry disease.
DESIGN: Genotyping for IL-10[819C/T; -592C/A]; IL-1beta[+3954 C/T; -511C/T]; IL-1alpha[-889C/T]; and TNF-alpha[-308G/A] was performed in 76 patients and correlated with MSSI sub-scores and with enzyme (alpha-galactosidase A) levels. Fifty, normal, age- and sex-matched volunteers were also genotyped.
RESULTS: Of 76 patients, 31 (41%) were males and 45 (59%) were females. There was no correlation between enzyme levels and any cytokine levels. Statistically significant differences were found in prevalence of TNF-alpha [-308G/A] genotypes: 84% GG in patients versus 63% GG in controls (p = 0.038) and for IL-1alpha [-889C/T] genotypes: 94% CC in patients versus 21% CC in controls (p < 0.001). Statistically significant differences were found in the ratio between the two polymorphisms of IL-10 (p < 0.0001), between the two polymorphisms of IL-1beta (p = 0.001); between IL-1alpha [-889C/T] and IL-1beta [3954C/T] (p = 0.002); and between IL-10[-592C/T] and IL-1beta [3954C/T] (p = 0.041). Correlations between TNF-alpha [-308G/A] and both kidney and neurological MSSI sub-scores (both: p = 0.06) and between IL-10[-819C/T] and the MSSI neurological score (p = 0.03) were noted. The majority of patients with Fabry disease have therefore a profile of low TNF-alpha (increased frequency of GG genotype of the TNF-alpha[-308] polymorphism), high IL-10 production (preponderance of the C allele of the wild type or heterozygous state for the polymorphisms of IL-10 [819; -592], but simultaneously increased production of the pro-inflammatory cytokines IL-1beta and IL-1alpha usually associated with a preponderance of the C allele of the wild type or heterozygous state for the polymorphisms of IL-1beta [3954; -511] and of IL-1 alpha[-889].
CONCLUSIONS: We speculate that sequence variations of important inflammatory genes of the interleukin inflammatory family are associated with differential effects in Fabry disease, and with increased sample size, haplotype blocks might be constructed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17353161

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  9 in total

Review 1.  Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders.

Authors:  Hui Chen; Annie Y Chan; Donald U Stone; Nawajes A Mandal
Journal:  Surv Ophthalmol       Date:  2013-09-05       Impact factor: 6.048

2.  Evidence for inflammation in Fabry's disease? Headache and muscle involvement responding to corticosteroid and methotrexate treatment.

Authors:  Markus Kraemer; N Karabul; P Berlit; A Rolfs
Journal:  J Neurol       Date:  2017-01-27       Impact factor: 4.849

3.  Subfoveal choroidal neovascularization in a patient with Fabry's disease.

Authors:  Andrea Sodi; Alessandro Bini; Renzo Mignani; Barbara Minuti; Ugo Menchini
Journal:  Int Ophthalmol       Date:  2008-09-11       Impact factor: 2.031

4.  Genetic polymorphisms of vitamin D receptor (VDR) in Fabry disease.

Authors:  Michael Teitcher; Sarah Weinerman; Catharina Whybra; Michael Beck; Nir Sharon; Deborah Elstein; Gheona Altarescu
Journal:  Genetica       Date:  2008-02-16       Impact factor: 1.082

5.  Fabry disease associated with multiple myeloma: a case report.

Authors:  Keika Adachi; Hirobumi Tokuyama; Yoichi Oshima; Tomoaki Itoh; Akinori Hashiguchi; Hiroyuki Yamakawa; Tadayasu Togawa; Hitoshi Sakuraba; Shu Wakino; Hiroshi Itoh
Journal:  CEN Case Rep       Date:  2021-09-16

Review 6.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

7.  Increased Serum Interleukin-6 and Tumor Necrosis Factor Alpha Levels in Fabry Disease: Correlation with Disease Burden.

Authors:  Nilton Salles Rosa Neto; Judith Campos de Barros Bento; Valéria de Falco Caparbo; Rosa Maria Rodrigues Pereira
Journal:  Clinics (Sao Paulo)       Date:  2021-07-16       Impact factor: 2.365

8.  Initially Nondiagnosed Fabry's Disease when Electron Microscopy Is Lacking: The Continuing Story of Focal and Segmental Glomerulosclerosis.

Authors:  H Trimarchi; A Karl; M S Raña; M Forrester; V Pomeranz; F Lombi; A Iotti
Journal:  Case Rep Nephrol Urol       Date:  2013-05-04

Review 9.  Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?

Authors:  Stephen Waldek; Sandro Feriozzi
Journal:  BMC Nephrol       Date:  2014-05-06       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.